spec sheet8 rows
Balipodect (TAK-063) is a selective phosphodiesterase 10A (PDE10A) inhibitor developed by Takeda as a potential antipsychotic for schizophrenia. It has completed phase 2 proof-of-concept testing and, as of 2026, was acquired by Axsome Therapeutics for further development.
- selective PDE10A inhibition tunes striatal dopamine signaling from inside the neuron, without direct D2-receptor blockade
- generally well tolerated in phase 1 and phase 2
- backed by an unusually complete translational package (PET target engagement, cross-species biomarkers)
- preclinical neuroprotection and motor recovery after striatal stroke (animal data only)
Overview
a selective PDE10A inhibitor (balipodect) that modulates striatal dopamine signaling via cAMP/cGMP instead of blocking D2; well tolerated with a strong translational story, but its phase 2 schizophrenia trial missed the primary endpoint. interesting preclinical stroke-recovery data.
- PDE10A sits almost only in the striatum, so inhibiting it targets one brain circuit unusually precisely.
- instead of blocking dopamine receptors like normal antipsychotics, it lets cAMP and cGMP build up inside striatal neurons.
- Takeda built a custom PET tracer just to prove the drug was hitting PDE10A in living human brains.
- in animals it helped motor recovery specifically after striatal stroke, but not after cortical stroke.
Mechanism
TAK-063 (balipodect) is a potent, selective inhibitor of phosphodiesterase 10A (PDE10A), a dual-substrate phosphodiesterase that is highly and selectively expressed in the medium spiny neurons of the striatum.
PDE10A degrades both cyclic AMP and cyclic GMP; by inhibiting it, TAK-063 raises striatal cyclic-nucleotide tone and thereby modulates signaling downstream of the receptors, shifting the balance between the direct (-driven) and indirect (-driven) output pathways from inside the neuron rather than by blocking surface dopamine receptors (Macek et al., 2020, Int J Neuropsychopharmacol, https://doi.org/10.1093/ijnp/pyaa042). the therapeutic hypothesis was an antipsychotic with a mechanism distinct from D2 antagonism and, potentially, a different side-effect profile.
Takeda built an unusually thorough translational package: a novel PET radiotracer confirmed PDE10A engagement in humans, and TAK-063 reduced ketamine-induced EEG and BOLD changes and produced cognition effects that tracked between animal models and healthy volunteers (Macek et al., 2020). in the clinic, however, the pivotal test fell short: according to PubMed, a phase 2 study in acute schizophrenia (NCT02477020) did not meet its primary endpoint of change in PANSS total score at week 6 (least-squares mean difference vs placebo -5.46, p=0.115; effect size 0.308), although secondary endpoints were generally supportive of antipsychotic activity and interpretation was confounded by a high placebo response and lack of an active reference (Macek et al., 2018, Schizophr Res, https://doi.org/10.1016/j.schres.2018.08.028). extrapyramidal-type events (akathisia, dystonia) were somewhat more common than placebo. beyond psychiatry, PDE10A inhibition by TAK-063 showed region-specific neuroprotection and repair in preclinical stroke: improved motor recovery and increased after striatal (but not cortical) stroke, and reduced infarct and inflammation in an ischemia model (Birjandi et al., 2020, Transl Stroke Res, https://doi.org/10.1007/s12975-020-00819-8; Beker et al., 2021, Mol Neurobiol, https://doi.org/10.1007/s12035-021-02621-5). the honest read: a mechanistically interesting, well-characterized striatal modulator whose antipsychotic promise did not clearly convert to a positive phase 2.
receptor fingerprint
Phosphodiesterase 10A (PDE10A)potent, selective inhibitor; blocks hydrolysis of cAMP and cGMP in striatal medium spiny neurons
striatal / cGMP signaling (downstream)raises cyclic nucleotide tone in medium spiny neurons, dampening D2-pathway and enhancing D1-pathway output
Safetyrisks and cautions, not medical advice
Balipodect has been evaluated in more than 360 individuals across phase 1 and phase 2 studies, including a 164-patient proof-of-concept trial in schizophrenia, and has shown a favorable safety and tolerability profile in these studies. A phase 1 study found it safe and well tolerated at single doses up to 1000 mg, with a pharmacokinetic profile supporting once-daily dosing. It remains investigational and is not approved for any indication; Axsome Therapeutics announced plans in 2026 to pursue phase 3 trial-enabling work for schizophrenia and Tourette syndrome.
History
TAK-063 was developed by Takeda as part of a wave of PDE10A inhibitors explored across the industry as a novel, non-D2 approach to schizophrenia. it was notable for its rigorous translational phase 1 strategy, including a purpose-built PDE10A PET tracer and back-and-forth validation of biomarkers between animals and humans. the phase 2 acute-schizophrenia trial in 2018 missed its primary PANSS endpoint despite some supportive secondary signals, which, along with the broader industry disappointment in PDE10A inhibitors for psychosis, limited its further development; later interest centered on preclinical neuroprotection.
Reputation
among CNS drug-development watchers, TAK-063 is cited as one of the better-characterized PDE10A inhibitors and as part of the cautionary arc of that whole target class: elegant striatal mechanism, strong translational science, but repeatedly underwhelming antipsychotic efficacy in the clinic. it is respected more as a research tool and case study than as a would-be medicine.
Subjective profileweighing the evidence above
Mechanistically elegant and well tolerated across more than 360 people, but tolerability is not efficacy and the antipsychotic effect is still unproven. Worth following now that Axsome has picked it up; not worth acting on until a trial says something about whether it works.
Resources
This entry is here for reference.
Research
- 2016first citedA phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-063,…
- 2019controlled trialA phase 2, randomized, placebo-controlled study of the efficacy and safety of TAK-063 in subjec…
- 2022most recentPhosphodiesterase 10A Is a Critical Target for Neuroprotection in a Mouse Model of Ischemic Str…
- 1.A phase 2, randomized, placebo-controlled study of the efficacy and safety of TAK-063 in subjects with an acute exacerbation of schizophrenia
- 2.Translational Development Strategies for TAK-063, a Phosphodiesterase 10A Inhibitor
- 3.Phosphodiesterase 10A Inhibition Leads to Brain Region-Specific Recovery Based on Stroke Type
- 4.Phosphodiesterase 10A Is a Critical Target for Neuroprotection in a Mouse Model of Ischemic Stroke.
- 5.A phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-063, a selective PDE10A inhibitor
5 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
what is TAK-063 (balipodect)?
it is a potent, selective inhibitor of phosphodiesterase 10A (PDE10A), an enzyme found almost exclusively in the medium spiny neurons of the striatum. by blocking PDE10A it raises the second messengers cAMP and cGMP inside those neurons, which tunes dopamine signaling downstream of the receptors rather than blocking the receptors directly (Macek et al., 2020, Int J Neuropsychopharmacol, https://doi.org/10.1093/ijnp/pyaa042).
what was it being developed for?
schizophrenia. the idea was an antipsychotic that works through the striatal cAMP/cGMP system instead of directly antagonizing dopamine D2 receptors, in the hope of treating psychosis with a different side-effect profile.
did it work in patients?
not clearly. in a phase 2 trial in people with an acute exacerbation of schizophrenia, 20 mg daily TAK-063 did not significantly beat placebo on the primary PANSS total score (difference vs placebo -5.46, p=0.115; effect size 0.308), though several secondary measures leaned toward antipsychotic activity and a high placebo response muddied interpretation (Macek et al., 2018, Schizophr Res, https://doi.org/10.1016/j.schres.2018.08.028).
was it well tolerated?
largely yes; most adverse events were mild to moderate and it was generally well tolerated in both healthy volunteers and schizophrenia patients across the phase 1 and phase 2 work. notably, extrapyramidal-type effects such as akathisia and dystonia were somewhat more frequent than placebo in the phase 2 study (Macek et al., 2018, Schizophr Res, https://doi.org/10.1016/j.schres.2018.08.028).
does it have any use outside schizophrenia?
in preclinical work, PDE10A inhibition with TAK-063 showed neuroprotective and repair effects after striatal stroke in animals; it improved motor recovery and raised striatal BDNF specifically after striatal (not cortical) stroke, and reduced injury in an ischemia model (Birjandi et al., 2020, Transl Stroke Res, https://doi.org/10.1007/s12975-020-00819-8; Beker et al., 2021, Mol Neurobiol, https://doi.org/10.1007/s12035-021-02621-5). these are animal findings only.
is it a nootropic i can take?
no. it is an investigational drug that did not clear its main efficacy hurdle in schizophrenia, and it is not sold as a supplement. it is included here as a well-studied example of the PDE10A-inhibitor approach to modulating striatal dopamine signaling.
how is PDE10A inhibition different from a normal antipsychotic?
standard antipsychotics block dopamine D2 receptors on the cell surface. PDE10A inhibitors instead let cAMP/cGMP build up inside striatal neurons, shifting the balance of the direct and indirect output pathways from the inside. the appeal was a potentially different, and hopefully gentler, way to get antipsychotic effects; the phase 2 result showed that translating this into clear clinical benefit is hard.